In addition to heterogeneity within the core KRAS pathway, we detected multiple additional pathways that were genetically altered at high frequency (>20%) in PDA (Fig. 5a, Supplementary Figs 31–33). The gene discussed is KRAS; the disease is Patent ductus arteriosus.